GlobeStar Therapeutics Corp - Quarter Report: 2022 March (Form 10-Q)

UNITED STATES

SECURITY AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________

FORM 10-Q

____________________

(MARK ONE)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number: 333-170315

GlobeStar Therapeutics Corporation

(Exact name of registrant as specified in its charter)

Wyoming		27-3480481
(State or other jurisdiction of Incorporation or organization)		(I.R.S. Employer Identification Number)

719 Jadwin Avenue, Richland, WA		99352
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: 206-451-1970

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☐
(Do not check is smaller reporting company)		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class	Trading Symbol	Name of each exchange on which registered
Common	GSTC	N/A

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of May 23, 2022, 642,912,782 shares of common stock issued and outstanding.

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION	4

Item 1. Financial Statements	4

Consolidated Balance Sheets as of March 31, 2022 (Unaudited) and September 30, 2021	4

Consolidated Statements of Operations for the Three and Six Months Ended March 31, 2022 and 2021 (Unaudited)	5

Consolidated Statements of Stockholders' Deficit for the Three and Six Months Ended March 31, 2022 and 2021 (Unaudited)	6

Consolidated Statements of Cash Flows for the Six Months Ended March 31, 2022 and 2021 (Unaudited)	7-8

Notes to the Unaudited Consolidated Financial Statements	9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3. Quantitative and Qualitative Disclosures about Market Risk	17

Item 4. Controls and Procedures	17

PART II — OTHER INFORMATION	18

Item 1. Legal Proceedings	18

Item 1A. Risk Factors	18

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	18

Item 3. Defaults upon Senior Securities	18

Item 4. Mine Safety Disclosures	18

Item 5. Other Information	18

Item 6. Exhibits	19

SIGNATURES	20

- 2 -

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan”, “anticipate”, “believe”, “estimate”, “should”, “expect” and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward - looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2021. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the “SEC”), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

OTHER PERTINENT INFORMATION

When used in this report, the terms, “we,” the “Company,” “our,” and “us” refers to GlobeStar Therapeutics Corporation, a Wyoming corporation and its subsidiaries unless the context specifically indicates otherwise.

- 3 -

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

GLOBESTAR THERAPEUTICS CORPORATION

CONSOLIDATED BALANCE SHEETS


		March 31, 2022			September 30, 2021
	(Unaudited)
CURRENT ASSETS
Cash and cash equivalents	$	576		$	5,960
Total current assets		576			5,960

TOTAL ASSETS	$	576		$	5,960

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	225,759		$	222,778
Accounts payable to related party		213,533			119,655
Advances payable		59,650			59,650
Current portion of convertible notes payable, net of discount of $0		20,000			20,000
Series G Preferred Stock Liability, net of discount of $39,453 and $30,745, respectively		331,547			86,130
Current portion of accrued interest payable		233,486			223,568

Total current liabilities		1,083,975			731,781

TOTAL LIABILITIES		1,083,975			731,781

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ DEFICIT
Common stock, $0.001 par value, unlimited shares authorized; 605,791,493 and 561,495,726 shares issued and outstanding at March 31, 2022 and September 30, 2021, respectively		605,790			561,494
Preferred stock; 20,000,000 shares authorized:
Series A Preferred Stock, $0.001 par value, 6,000,000 shares authorized, 0 shares issued and outstanding at March 31, 2022 and September 30, 2021		—			—
Series D Preferred Stock, $0.001 par value, 539,988 shares authorized; 509,988 shares issued and outstanding at March 31, 2022 and September 30, 2021		510			510
Series E Preferred Stock, $0.001 par value, 1,000,000 shares authorized; 1,000,000 shares issued and outstanding at March 31, 2022 and September 30, 2021		1,000			1,000
Series F Preferred Stock; $0.001 par value, 501,975 shares authorized; 257,984 and 386,975 shares issued and outstanding at March 31, 2022 and September 30, 2021, respectively		258			387
Additional paid-in capital		16,347,408			15,228,254
Stock payable, consisting of 0 and 25,980,000 shares to be issued at March 31, 2022 and September 30, 2021, respectively		—			499,500
Accumulated deficit		(18,038,365	)		(17,016,966	)

TOTAL STOCKHOLDERS’ DEFICIT		(1,083,399	)		(725,821	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	576		$	5,960

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 4 -

GLOBESTAR THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)


	Three Months Ended						Six Months Ended
	March 31,						March 31,
	2022			2021			2022			2021

REVENUE	$	—		$	—		$	—		$	—
Cost of goods sold		—			2,412			—			2,412

Gross margin		—			(2,412	)		—			(2,412	)

OPERATING EXPENSES
General and administrative expenses		662,310			467,991			828,604			528,344
Total operating expenses		662,310			467,991			828,604			528,344

LOSS FROM OPERATIONS		(662,310	)		(470,403	)		(828,604	)		(530,756	)

OTHER INCOME (EXPENSE)
Loss on settlement of liabilities		—			(311,762	)		(146,460	)		(311,762	)
Interest expense		(26,248	)		(113,666	)		(46,335	)		(177,708	)
Total other income (expense)		(26,248	)		(425,428	)		(192,795	)		(489,470	)

Net loss	$	(688,558	)	$	(895,831	)	$	(1,021,399	)	$	(1,020,226	)

Net loss per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average shares outstanding - basic and diluted		600,796,122			469,027,746			586,965,040			457,766,883

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 5 -

GLOBESTAR THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)


																		Original
				Series A			Series D			Series E					Series F			Additional
	Common Stock			Preferred Stock			Preferred Stock			Preferred Stock					Preferred Stock			Paid-in			Stock		Accumulated			Total
	Shares	Par		Shares	Amount		Shares	Amount		Shares		Amount			Shares	Amount		Capital			Payable		Deficit			Deficit

Balance, September 30, 2020	436,218,342	$	436,217	—	$	—	509,988	$	510	1,000,000		$	1,000		386,975	$	387	$	6,118,002		$	—	$	(7,215,338	)	$	(659,222	)

Common stock issued for conversion of convertible note payable and accrued interest	19,269,286		19,269	—		—	—		—	—			—		—		—		45,391			—		—			64,660
Beneficial conversion discount on convertible notes payable	—		—	—		—	—		—	—			—		—		—		30,000			—		—			30,000
Net loss for the three months ended December 31, 2020	—		—	—		—	—		—	—			—		—		—		—			—		(124,395	)		(124,395	)
Balance, December 31, 2020	455,487,628		455,486	—		—	509,988		510	1,000,000			1,000		386,975		387		6,193,393			—		(7,339,733	)		(688,957	)

Issuance of common stock and retirement of accrued compensation with former officer	2,600,000		2,600	—		—	—		—	—			—		—		—		132,600			312,000		—			447,200
Common stock issued for conversion of convertible note payable and accrued interest	17,551,147		17,552	—		—	—		—	—			—		—		—		97,990			—		—			115,542
Sale of common stock units for cash proceeds	—		—	—		—	—		—	—			—		—		—		—			499,500		—			499,500
Repurchase of preferred stock from former officer	—		—	—		—	—		—	(1,000,000	)		(1,000	)	—		—		(324,000	)		—		—			(325,000	)
Issuance of preferred stock to officer	—		—	—		—	—		—	1,000,000			1,000		—		—		324,000			—		—			325,000
Settlement of accounts payable with related party	—		—	—		—	—		—	—			—		—		—		38,130			—		—			38,130
Beneficial conversion discount on convertible notes payable	—		—	—		—	—		—	—			—		—		—		100,000			—		—			100,000
Net loss for the three months ended March 31, 2021	—		—	—		—	—		—	—			—		—		—		—			—		(895,831	)		(895,831	)
Balance, March 31, 2021	475,638,775	$	475,638	—	$	—	509,988	$	510	1,000,000		$	1,000		386,975	$	387	$	6,562,113		$	811,500	$	(8,235,564	)	$	(384,416	)

- 6 -


																		Original
				Series A			Series D			Series E			Series F					Additional
	Common Stock			Preferred Stock			Preferred Stock			Preferred Stock			Preferred Stock					Paid-in			Stock			Accumulated			Total
	Shares	Par		Shares	Amount		Shares	Amount		Shares	Amount		Shares		Amount			Capital			Payable			Deficit			Deficit


Balance, September 30, 2021	561,495,726	$	561,494	—	$	—	509,988	$	510	1,000,000	$	1,000	386,975		$	387		$	15,228,254		$	499,500		$	(17,016,966	)	$	(725,821	)

Conversion of Series F Preferred Stock to common	12,899,100		12,899	—		—	—		—	—		—	(128,991	)		(129	)		(12,770	)		—			—			—
Common stock issued for stock payable	19,980,000		19,980	—		—	—		—	—		—	—			—			479,520			(499,500	)		—			—
Common stock issued for settlement of liability	6,000,000		6,000	—		—	—		—	—		—	—			—			155,460			—			—			161,460
Net loss for the three months ended December 31, 2021	—		—	—		—	—		—	—		—	—			—			—			—			(332,841	)		(332,841	)
Balance, December 31, 2021	600,374,826		600,373	—		—	509,988		510	1,000,000		1,000	257,984			258			15,850,464			—			(17,349,807	)		(897,202	)

Conversion of Series G Preferred Stock to common	5,416,667		5,417	—		—	—		—	—		—	—			—			20,583			—			—			26,000
Stock-based compensation	—		—	—		—	—		—	—		—	—			—			322,266			—			—			322,266
Stock-based compensation, related parties	—		—	—		—	—		—	—		—	—			—			154,095			—			—			154,095
Net loss for the three months ended March 31, 2022	—		—	—		—	—		—	—		—	—			—			—			—			(688,558	)		(688,558	)
Balance, March 31, 2022	605,791,493	$	605,790	—	$	—	509,988	$	510	1,000,000	$	1,000	257,984		$	258		$	16,347,408		$	—		$	(18,038,365	)	$	(1,083,399	)

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 7 -

GLOBESTAR THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Six Months Ended
	March 31,
	2022			2021
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$	(1,021,399	)	$	(1,020,226	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation		322,266			325,000
Stock compensation, related parties		154,095			—
Depreciation		—			1,275
Loss on settlement of liabilities		146,460			311,762
Amortization of discount on convertible note payable		35,417			168,912
Changes in operating assets and liabilities
Inventory		—			2,412
Prepaid expenses		—			4,783
Accounts payable and accrued liabilities		17,981			5,232
Accounts payable and accrued liabilities to related party		93,878			—
Accrued interest payable		10,918			8,796
NET CASH USED IN OPERATING ACTIVITIES		(240,384	)		(192,054	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from convertible notes payable, net		—			95,000
Repurchase of preferred stock from former officer		—			(325,000	)
Proceeds from sale of common stock		—			499,500
Proceeds from sale of share - settled Series G preferred stock		235,000			—
NET CASH PROVIDED BY FINANCING ACTIVITIES		235,000			269,500

NET CHANGE IN CASH AND CASH EQUIVALENTS		(5,384	)		77,446

Cash and cash equivalents at beginning of period		5,960			81,442

Cash and cash equivalents at end of period	$	576		$	158,888

Cash paid during the period for:
Interest	$	—		$	—
Taxes	$	—		$	—

Noncash investing and financing transactions:
Conversion of convertible notes payable and accrued interest into common stock	$	—		$	180,202
Beneficial conversion discount on convertible notes payable	$	—		$	130,000
Conversion of Series F Preferred Stock to common stock	$	12,899		$	—
Conversion of Series G Preferred Stock to common stock	$	25,000		$	—
Common stock issued for stock payable	$	499,500		$	—
Common stock issued for settlement of liability	$	15,000		$	135,438
Settlement of liabilities with related party	$	—		$	38,130

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 8 -

GLOBESTAR THERAPEUTICS CORPORATION

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2022

(Unaudited)

Note 1. General Organization and Business

GlobeStar Therapeutics Corporation (the “Company”) was incorporated on April 29, 2016. The Company’s year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation.

The Company is developing an expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases. The potential pharmaceutical products related to treatment for multiple sclerosis are licensed to the Company through the worldwide licensing agreement described in Note 6.

Note 2. Going Concern and Summary of Significant Accounting Policies

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the six months ended March 31, 2022, the Company had a net loss of $1,021,399 and cash flow used in operating activities of $240,384. As of March 31, 2022, the Company had negative working capital of $1,083,399. Management does not anticipate having positive cash flow from operations in the near future. The Company has minimal revenue. Without additional capital, the Company will not be able to remain in business.

These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

Management has plans to address the Company’s financial situation as follows:

In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern.

In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

Interim Financial Statements

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X and should be read in conjunction with the audited financial statements and notes thereto for the year ended September 30, 2021 which are included on our Form 10-K filed on January 5, 2022. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the six months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2023.

Consolidated Financial Statements

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

- 9 -

Recently Issued Accounting Pronouncements

We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

Note 3. Convertible Notes Payable

Convertible notes payable consisted of the following at March 31, 2022 and September 30, 2021:


	March 31, 2022		September 30, 2021
Convertible note dated April 13, 2017 in the original principal amount of $20,000, no stated maturity date, bearing interest at 3% per year, convertible into common stock at a rate of $0.01 per share.	$	20,000	$	20,000

Total current convertible notes payable, net of discount	$	20,000	$	20,000

All principal along with accrued interest is payable on the maturity date. The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.99% of the outstanding stock of the Company.

During the three months ended December 31, 2020, the Company recognized $3,000 of deferred finance costs from its new convertible note payable and $30,000 of new discount related to the beneficial conversion features of convertible notes payable. During the three months ended March 31, 2021, the Company recognized $7,000 of deferred finance costs from its new convertible note payable and $100,000 of new discount related to the beneficial conversion features of convertible notes payable.

During the three and six months ended March 31, 2021, the Company recognized interest expense on convertible notes of $5,942 and $8,796 and amortization of discount on convertible notes payable of $61,188 and $168,912, respectively.

As of March 31, 2022 and September 30, 2021, accrued interest on convertible notes payable was $222,287.

Advances

As of March 31, 2022 and September 30, 2021, the Company had non-interest bearing advances payable to third parties of $59,650. These advances are payable on demand.

Note 4. Related Party Transactions

In January 2021, the Company’s former Chief Executive Officer Sydney Jim agreed to forgive all accrued but unpaid compensation of $38,130, resulting in a gain on settlement of liabilities to the Company that was recorded to additional paid in capital.

In March 2021, the Company entered into severance agreement with its former CEO Alex Blankenship. The Company owed Ms. Blankenship unpaid compensation of $130,000 and agreed to issue 8,600,000 shares of common stock in full settlement of this amount and release from the employment agreement with her. The shares had a fair value of $447,200 based on the stock price at the date of the agreement. The Company recognized a loss on settlement of $317,200 in connection with this agreement. As of March 31, 2021, 2,600,000 of the shares were issued to Ms. Blankenship. Concurrently with the severance agreement, the Company agreed to purchase the 1,000,000 shares Series E Preferred Stock held by Ms. Blankenship for $325,000 in cash. The Company reissued those Series E preferred Shares to the Company’s new CEO James Katzaroff. The Company recognized stock-based compensation of $325,000 related to this reissuance.

In February 2022, the Company entered into an amended and restatement employment agreement with Jim Katzaroff, the CEO. Mr. Katzaroff is entitled to an annual salary of $180,000 and a bonus as determined by the Board of Directors. Mr. Katzaroff may elect to receive payment in shares of stock based on the average of the three lowest trading prices for the 15 days prior to election of payment in stock. Further, in the event of a change of control of the Company, Mr. Katzaroff is entitled to a payment equal to 2.99 multiplied by the larger of the total compensation paid to Mr. Katzaroff over the prior 12-month period or the average compensation paid or payable to the Consultant over the prior three years.

- 10 -

The Company awarded Mr. Katzaroff a total of 35,000,000 common stock options with an exercise price of $0.009 per share, an exercise term of five years. The options vest 50% immediately, and the remainder on monthly basis over two years. Mr. Katzaroff is also entitled to additional options in the event of the Company issuing equity or equity equivalents in the future, with him receiving an equal amount of options as those instruments that are issued. The exercise price of these additional options will be 110% of the price per equity equivalent.

Additionally, Mr. Katzaroff will earn a fee related to an strategic transaction, as defined in the agreement, including but not limited to acquisitions, divestitures, partnerships or joint ventures, of at least 2% for any transactions not introduced by Mr. Katzaroff, or 4% for any introduced by Mr. Katzroff of up to $20,000,000, and an additional 0.75% - 3.5% for amounts above that threshold.

Mr. Katzroff will also receive an activity fee of 3% of gross revenues related to activities including securing a variety of vendor, sales or advertising relationships, or any new revenue generating activity. If such activity is a cost saving initiative instead of revenue generating, Mr. Katzaroff will receive 10% of the cost savings.

As of March 31, 2022 and September 30, 2021, the Company owed $213,533 and $161,655 to officers of the Company for compensation, respectively.

During the year ended September 30, 2021, the Company issued 5,000,000 shares of common stock to its CFO Robert Chicoski, with a fair value of $75,000 as a finder’s fee related to the Company’s license agreement.

Note 5. Stockholders’ Deficit

Preferred Stock

Series A Preferred Stock – Our board of directors has designated up to 6,000,000 shares of Series A Preferred Stock. The Series A Preferred Stock has a liquidation value of $2.00 per share. The initial number issued is 5,000,000 with additional shares to be issued as a dividend not to exceed a total of 6,000,000 shares. The rank of the Series A is prior to all common and preferred shares. In addition, the Series A Preferred Stock retains protective provisions to maintain their seniority with respect to liquidation or dissolution. The Series A Preferred Stock holds no voting rights and earns an 8% per annum dividend, payable in additional shares of Series A Preferred Stock. At March 31, 2022 and September 30, 2021, there were no shares of our Series A Preferred Stock outstanding, respectively.

Series B Preferred Stock – Our board of directors has designated up to 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock has a liquidation value of $1.00 per share. The holders of the Series B Preferred Stock are entitled to dividends of 8% per year payable quarterly in cash or in shares of common stock at the option of the Company. The holders of the Series B Preferred Stock have no voting rights. The Series B Preferred Stock is redeemable at the option of the Company at a price of $1.00 per share. At March 31, 2022 and September 30, 2021, there were no shares of our Series B Preferred Stock outstanding.

Series C Preferred Stock – On September 12, 2017, our board of directors designated up to 1,200,000 shares of Series C Preferred Stock with a liquidation value of $0.50 per share. The holders of the Series C Preferred Stock have no voting rights. The Series C Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of one share of common stock for each share of Series C Preferred Stock. The Series C Preferred Stock is redeemable at the option of the Company at a price of $0.50 per share. The Series C Preferred Stock has been canceled, and there are no shares of Series C Preferred Stock outstanding as of March 31, 2022 and September 30, 2021.

Series D Preferred Stock – On September 21, 2017, our board of directors designated up to 539,988 shares of Series D Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series D Preferred Stock have no voting rights. The Series D Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series D Preferred Stock is not redeemable. During the year ended September 30, 2019, the holders of 60,000 shares of the Series D Preferred stock returned these shares to the Company for cancellation. There was no gain or loss recognized on this transaction. At March 31, 2022 and September 30, 2021, there were 509,988 shares of Series D Preferred Stock outstanding.

Series E Preferred Stock – On August 3, 2015, our board of directors designated 1,000,000 shares of Series E Preferred stock. The Series E Preferred stock is subordinate to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock retained 2/3 of the voting rights in the Company.

At March 31, 2022 and September 30, 2021, there were 1,000,000 shares of Series E Preferred stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes.

- 11 -

Series F Preferred Stock – On September 21, 2017, our board of directors designated up to 501,975 shares of Series F Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series F Preferred Stock have no voting rights. The Series F Preferred Stock is convertible at the option of the holder into shares of common stock at a rate of $0.01 per share of common stock. The Series F Preferred Stock is not redeemable. During the year ended September 30, 2019, 60,000 shares of the Series F Preferred Stock were returned for cancellation. On November 5, 2021, a holder of Series F Preferred Stock converted 128,991 shares of Series F into 12,899,100 shares of common stock of the Company in accordance with the terms of the Series F. At March 31, 2022 and September 30, 2021, 257,984 and 386,975 shares of the Series F Preferred Stock were issued and outstanding, respectively.

Series G Preferred Stock - On August 11, 2021, our board of directors designated up to 1,000,000 shares of Series G Preferred Stock with a liquidation value of $1.00 per share. The holders of the Series G Preferred Stock have no voting rights except on matters related specifically to the Series G Preferred Stock. The Series G Preferred Stock carries a dividend of 8% of the stated value per share, which is cumulative and payable upon redemption, liquidation or conversion, and increases to 22% in case of default. The Series G Preferred Stock and accrued dividends are convertible beginning 180 days from issuance at the option of the holder into shares of common stock at a rate of a conversion price of 75% of the average three lowest trading prices during the 15 days prior to conversion. The Company will be required to redeem the Series G Preferred Stock upon the earlier of 15 months from issuance date or upon on event of default as defined in the agreement.

Based on the economic characteristics of the Series G Preferred Stock, the Company determined that the Series G should be accounted for as a liability under ASC 480-10, based on the discounted conversion price providing an effectively fixed monetary amount that the preferred stock is convertible into.

During the six months ended March 31, 2022, the Company sold an aggregate of 279,125 shares of Series G Preferred Stock for net cash proceeds of $235,000. The Company recorded a debt discount of $44,125 for the difference between the cash proceeds and the total amount to be redeemed by the holder of $279,125. The Company amortized $35,417 of discount related to Series G Preferred Stock for the six months ended March 31, 2022. The dividends on the Series G Preferred Stock are accrued as interest. The Company recognized $10,918 of interest on the Series G Preferred Stock and had an accrued interest balance of $12,199 and $1,281 as of March 31, 2022 and September 30, 2021, respectively. During the three months ended March 31, 2022, the holder of the Series G converted 25,000 shares of Series G into 5,416,667 shares of common stock.

At March 31, 2022 and September 30, 2021, 347,625 and 93,500 shares of the Series G Preferred Stock were issued and outstanding, respectively.

Common stock issued for conversion of convertible notes payable

During the six months ended March 31, 2021, the Company issued 36,820,433 shares of common stock upon the conversion of principal of $170,000 and accrued interest of $10,200. There was no gain or loss recognized as the conversion occurred in accordance with the original terms of the agreement. There were no conversions of convertible notes during the six months ended March 31, 2022

Common stock issued for stock payable

In December 2021, the Company issue 19,980,000 shares of common stock as part of the common stock unit sales that occurred during the year ended September 30, 2021. No shares are remaining to be issued for these unit sales.

Common Stock Warrants

The following table summarizes the stock warrant activity for the six months ended March 31, 2022:

	Warrants		Weighted- Average Exercise Price Per Share
Outstanding, September 30, 2021		29,970,000	$	0.03
Granted		39,900,000	$	0.01
Exercised		—	$	—
Forfeited		—	$	—
Expired		—	$	—
Outstanding, March 31, 2022		69,870,000	$	0.02

As of March 31, 2022, the outstanding warrants had an expected remaining life of 3.53 years and have no intrinsic value.

- 12 -

Common stock issued for settlement of liabilities

During the six months ended March 31, 2022, the Company issued 6,000,000 shares of common stock and 900,000 warrants for the settlement of liabilities totaling $15,000. The Company recorded a $146,460 loss on settlement of liabilities related to this transaction.

Common Stock Options

As discussed in Note 4, The Company awarded common stock options to Mr. Katzaroff in connection with his amended and restated employment agreement. The Company estimated the fair value of the options to be $289,198, using the following assumptions: 1) volatility of 177.43%; 2) risk free rate of 1.3%; 3) dividend yield of 0% and 4) expected term of 5 years. The Company recognized $154,095 of expense related to the fair value of options vesting during the three months ended March 31, 2022. The Company expects to recognize an additional $104,460 of expense related to these options assuming all vest.

The following table summarizes the stock option activity for the six months ended March 31, 2022:

	Options		Weighted- Average Exercise Price Per Share
Outstanding, September 30, 2021		70,000,000	$	0.03
Granted		35,000,000	$	0.01
Exercised		—	$	—
Forfeited		—	$	—
Expired		—	$	—
Outstanding, March 31, 2022		105,000,000	$	0.02

As of March 31, 2022, all outstanding options had an expected remaining life of 2.36 years and have no intrinsic value.

Beneficial conversion feature

During the six months ended March 31, 2021, the Company charged to additional paid-in capital the aggregate amount of $130,000 on connection with the beneficial conversion feature of notes payable.

Note 6. License Agreement

Effective August 23, 2020 the Company’s wholly-owned subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis. In consideration for the license agreement, SomaCeuticals agreed to pay 7 to Stand a royalty of 7.1% of the net sales of any product developed under the patent on a worldwide basis. Additionally, the Company will issue shares of common stock to 7 to Stand upon completion of the following milestones:

	●	Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company will issue 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021.

	●	29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021.

	●	29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and

	●	Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met.

	●	$40,000 of royalties to be paid to 7 to Stand annually, on a quarterly basis. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval.

- 13 -

The Company paid $40,000 in royalties during the three months ended March 31, 2022 and owes $16,250 of royalties and late fees under this agreement as of March 31, 2022.

Note 7. Commitments

In February 2022, the Company entered into a consulting agreement with Spivak Management, Inc. (the “Consultant”). Under the agreement, the Consultant will provide business strategy advice and introductions to the Company fir a period of five years unless mutually terminated sooner. Concurrently, the Consultant entered into a stock purchase agreement with the Company to purchase 6,000,000 shares of common stock for $25,000 cash. The purchase and issuance of the shares will be completed by June 30, 2022.

The Consultant will be paid a signing bonus of $25,000 upon receipt by the Company of the $25,000 cash under the stock purchase agreement described above. The Consultant will also receive the larger of $12,500 per month, or 50% of the CEO’s fixed cash compensation under the amended employment agreement described in Note 4. The Consultant may elect to receive this payment in stock.

The Consultant may also receive a bonus in each calendar year of the agreement equal to the larger of any bonus awarded by the Board of Directors to the Consultant or 50% of the largest bonus payable by the Company to anyone other than the Consultant. If the agreement is terminated with one year of a change of control of the Company, the Consultant will be entitled to receive a payment equal to 2.99 times the larger of the total compensation paid to the Consultant over the prior 12 month period or the average compensation paid or payable to the Consultant over the prior three years.

The Consultant also received 39,000,000 warrants with an exercise price of $0.009 per share, and an exercise period of 5 years. The Company estimated the fair value of the warrants to be $322,266 which was recognized as general and administrative expense during the three months ended March 31, 2022, using the following assumptions: 1) volatility of 254.4%; 2) risk free rate of 1.76%; 3) dividend yield of 0% and 4) expected term of 5 years. The Consultant is also entitled to additional warrants in the event of the Company issuing equity or equity equivalents in the future, with the Consultant receiving an equal amount of warrants as those instruments that are issued. The exercise price of these additional warrants will be 110% of the price per equity equivalent, and they will vest 50% immediately and the remainder over two years.

Note 8. Subsequent Events

Subsequent to March 31, 2022, the holders of the Series G Preferred Stock converted a total of 158,625 shares and dividends of $6,345 into 37,121,289 shares of common stock.

- 14 -

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

We changed our name to GlobeStar Therapeutics Corporation on April 27, 2021 to better reflect our expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases.

GlobeStar Therapeutics Corporation, based in Richland Washington, is a clinical stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. GlobeStar Therapeutics owns the exclusive global license from the inventors, who are based in Italy. GlobeStar Therapeutics is initiating discussions with the FDA on clinical trial design in preparation for FDA submission and approval pathway.

Prior to the Company’s current business plan, the Company was a wellness company dedicated to bringing innovative, effective and high-quality supplement products to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals^TM

Professional Team

We have adopted a Medical Advisory Board and appointed medical doctors and medical professionals that have extensive education and hands on experience with pharmaceutical and nutraceutical solution for prevention and treatment of disease.

Management’s Plan to Attract Capital

In the near term, management will utilize equity and debt financing to complete assembling the professional and management team to commence the process for clinical trials in compliance with FDA protocol. plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern.

In the midterm, management will enhance its capital position with a public offering of equity securities to finance clinical trials and the necessary actions to obtain approval of worldwide marketing of our MS treatment

In the long term, marketing the Company’s pharmaceutical and nutraceutical products will provide the necessary cash flow to support future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of capital to support near term and midterm business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to support its operations.

Corporate Governance

We have adopted codes and committees for governance of the corporation that include: (i) audit committee charter, (ii) written acknowledgement of code of ethics for directors and senior officers, (iii) compensation committee charter, (iv) confidential information policy, iv) corporate governance guidelines, (vi) executive committee charter, and (vii) nominating committee charter.

Critical Accounting Policies

We prepare our consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the consolidated financial statements are prepared. We regularly review our accounting policies, and how they are applied and disclosed in our consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

- 15 -

Results of Operations

Three Months Ended March 31, 2022 Compared to the Three Months Ended March 31, 2021

Revenue. We had no revenue for the three months ended March 31, 2022 and 2021.

Cost of goods sold. We had $0 and $2,412 cost of goods sold for the three months ended March 31, 2022 and 2021, respectively related to the write down of inventory kept by the Company’s former CEO as part of the severance agreement.

General and administrative expense. We recognized general and administrative expense of $662,310 for the three months ended March 31, 2022 compared to $467,991 for the comparable period of 2021. The increase in general and administrative expense was related primarily to stock-based compensation of $154,095 related to the options issued to the CEO in 2022 and a $56,250 increase in royalty expense in 2022, which were offset by decreased legal fees of $20,880.

Loss on settlement of liabilities. We recognized a loss on the settlement of liabilities $311,762 during the three months ended March 31, 2021. The loss was related to the severance agreement with Alex Blankenship, our former CEO, resulting in a $311,762 loss.

Interest expense. We recognized interest expense of $26,248 for the six months ended March 31, 2022 compared to $113,666 for the comparable period of 2021. The decrease was due primarily to the amortization of the discount on convertible notes payable during the current period in the amount of $19,664 compared to $107,724 during the comparable period of the prior year.

Net loss. For the reasons above, we recognized a net loss of $688,558 for the three months ended March 31, 2022 compared to $895,831 for the three months ended March 31, 2021.

Six Months Ended March 31, 2022 Compared to the Six Months Ended March 31, 2021

Revenue. We had no revenue for the six months ended March 31, 2022 and 2021.

Cost of goods sold. We had cost of goods sold of $0 for the six months ended March 31, 2022 compared to $2,412 for the six months ended March 31, 2021 related to the write down of inventory kept by the Company’s former CEO as part of the severance agreement.

General and administrative expense. We recognized general and administrative expense of $828,604 for the six months ended March 31, 2022 compared to $528,344 for the comparable period of 2021. The increase in general and administrative expense was related primarily to stock-based compensation of $154,095 related to the options issued to the CEO in 2022, $322,266 related to warrants issued to a consultant and increased officer compensation of $56,438 primarily due to a bonus, a $56,250 increase in royalty expense and increased legal and consulting fees of $31,345 in 2022.

Loss on settlement of liabilities. We recognized $146,460 and $311,762 loss on the settlement of liabilities during the six months ended March 31, 2022 and 2021. In 2022, the loss was related the issuance of 6,000,0000 shares of common stock and 900,000 warrants for the settlement of liabilities. In 2021, the loss was related to the severance agreement with Alex Blankenship, our former CEO.

Interest expense. We recognized interest expense of $46,335 for the six months ended March 31, 2022 compared to $177,708 for the comparable period of 2021. The decrease was due primarily to the amortization of the discount on convertible notes payable during the current period in the amount of $35,417 compared to $168,912 during the comparable period of the prior year.

Net loss. For the reasons above, we recognized a net loss of $1,021,399 for the six months ended March 31, 2022 compared to $1,020,226 for the six months ended March 31, 2021.

Liquidity and Capital Resources

At March 31, 2022, we had cash on hand of $576. The Company has negative working capital of $1,083,399. Net cash used in operating activities for the six months ended March 31, 2022 was $240,384. Cash on hand is not adequate to fund our operations for less than twelve months. We do not expect to achieve positive cash flow from operating activities in the near future. We will require additional cash in order to implement our business plan. There is no guarantee that we will be able to attain fund when we need them or that funds will be available on terms that are acceptable to the Company. We have no material commitments for capital expenditures as of March 31, 2022.

- 16 -

During the six months ended March 31, 2022, the Company used cash in operating activities in the amount of $240,384. This consisted of the net loss of $1,021,399, partially offset by the following non-cash operating expenses: stock compensation of $322,266, stock compensation, related parties of $154,095, amortization of discount of $35,417 and loss on the settlement of liabilities of $146,460. The Company had cash flows from financing activities of $235,000 from the proceeds of sale of Series G Preferred Stock.

Additional Financing

Additional financing is required to continue operations. Although actively searching for available capital, the Company does not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

Off Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to a smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES

Management’s Report on Internal Control over Financial Reporting

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2022. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of March 31, 2022, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed by us under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

1.	As of March 31, 2022, we did not maintain effective controls over the control environment. Specifically, we have not developed and effectively communicated to our employees our accounting policies and procedures. This has resulted in inconsistent practices. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

2.	As of March 31, 2022, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

Our management, including our principal executive officer and principal financial officer do not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Change in Internal Controls Over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

- 17 -

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder are an adverse party or has a material interest adverse to us.

ITEM 1A. RISK FACTORS

Not applicable to a smaller reporting company.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Set forth below is information regarding the securities sold during the quarter ended March 31, 2022 that were not registered under the Securities Act:

Date of Sale	Title of Security	Number Sold		Consideration Received and Description of Underwriting or Other Discounts to Market Price or Convertible Security, Afforded to Purchasers	Exemption from Registration Claimed	If Option, Warrant or Convertible Security, terms of exercise or conversion

March 24, 2022	Common Stock		5,416,667	Conversion of Series G Preferred Stock	Section 3(a)(9) of the Securities Act	$0.001

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

The Company has not defaulted upon senior securities.

ITEM 4. MINE SAFETY DISCLOSURES

This item is not applicable.

ITEM 5. OTHER INFORMATION

None.

- 18 -

ITEM 6. EXHIBITS

3.1	Articles of Incorporation (1)
3.2	Bylaws (2)
14.1	Code of Ethics (3)
31.1	Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer (4)
31.2	Rule 13(a)-14(a)/15(d)-14(a) Certification of principal financial officer (4)
32.1	Section 1350 Certification of principal executive officer (4)
32.2	Section 1350 Certification of principal financial officer (4)
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. (5)
101.SCH	Inline XBRL Taxonomy Extension Schema Document (5)
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document (5)
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document (5)
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document (5)
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) (5)

__________

(1)	Incorporated by reference to our Definitive Proxy Statement on Schedule 14A filed on April 8, 2015.
(2)	Incorporated by reference to our Form 10-K/A Amendment No. 1 for the year ended September 30, 2015 filed on January 22, 2016.
(3)	Incorporated by reference to our Form S-1 filed with the Securities and Exchange Commission on November 3, 2010.
(4)	Filed or furnished herewith.
(5)	In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed.”

- 19 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GlobeStar Therapeutics Corporation

Date: June 1, 2022	By: /s/ James C. Katzaroff
	James C. Katzaroff
	Chief Executive Officer, President, Secretary, Principal Executive Officer and Director

Date: June 1, 2022	By: /s/ Robert Chicoski
	Robert Chicoski
	Chief Financial Officer, Treasurer, Secretary, Principal Financial and Accounting Officer

- 20 -